These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 33674839)

  • 1. Verification of Harmonization of Serum Total and Free Prostate-Specific Antigen (PSA) Measurements and Implications for Medical Decisions.
    Ferraro S; Bussetti M; Rizzardi S; Braga F; Panteghini M
    Clin Chem; 2021 Mar; 67(3):543-553. PubMed ID: 33674839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing the impact of inter-method bias of prostate specific antigen assays on biopsy referral: the key to move towards precision health in prostate cancer management.
    Ferraro S; Biganzoli G; Bussetti M; Castaldi S; Biganzoli EM; Plebani M
    Clin Chem Lab Med; 2023 Jan; 61(1):142-153. PubMed ID: 36322977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discordant prostate specific antigen test results despite WHO assay standardization.
    Boegemann M; Arsov C; Hadaschik B; Herkommer K; Imkamp F; Nofer JR; Gerß J; Albers P; Semjonow A
    Int J Biol Markers; 2018 Aug; 33(3):275-282. PubMed ID: 29734838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update.
    Stephan C; Klaas M; Müller C; Schnorr D; Loening SA; Jung K
    Clin Chem; 2006 Jan; 52(1):59-64. PubMed ID: 16391327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermethod differences in results for total PSA, free PSA, and percentage of free PSA.
    Slev PR; La'ulu SL; Roberts WL
    Am J Clin Pathol; 2008 Jun; 129(6):952-8. PubMed ID: 18480013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological variation estimates for prostate specific antigen from the European Biological Variation Study; consequences for diagnosis and monitoring of prostate cancer.
    Carobene A; Guerra E; Locatelli M; Cucchiara V; Briganti A; Aarsand AK; Coşkun A; Díaz-Garzón J; Fernandez-Calle P; Røraas T; Sandberg S; Jonker N; Ceriotti F; ;
    Clin Chim Acta; 2018 Nov; 486():185-191. PubMed ID: 30063887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic Differences Between Total and Free Prostate-Specific Antigen Immunoassays: Comparison Using Passing and Bablok Regression.
    Serdarevic N; Dabla P; Stanciu AE
    Indian J Clin Biochem; 2021 Apr; 36(2):151-158. PubMed ID: 33867705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Three Assays for Total and Free PSA Using Hybritech and WHO Calibrations.
    Garrido MM; Marta JC; Ribeiro RM; Pinheiro LC; Holdenrieder S; Guimarães JT
    In Vivo; 2021; 35(6):3431-3439. PubMed ID: 34697179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interassay Variability and Clinical Implications of Five Different Prostate-specific Antigen Assays.
    Kaufmann B; Pellegrino P; Zuluaga L; Ben-David R; Müntener M; Keller EX; Spanaus K; von Eckardstein A; Gorin MA; Poyet C
    Eur Urol Open Sci; 2024 May; 63():4-12. PubMed ID: 38558765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
    Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
    Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards.
    Stephan C; Kahrs AM; Klotzek S; Reiche J; Müller C; Lein M; Deger S; Miller K; Jung K
    Clin Chem Lab Med; 2008; 46(5):623-9. PubMed ID: 18839463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of non-alpha1-antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen: analytical performance and diagnostic accuracy.
    Wesseling S; Stephan C; Semjonow A; Lein M; Brux B; Sinha P; Loening SA; Jung K
    Clin Chem; 2003 Jun; 49(6 Pt 1):887-94. PubMed ID: 12765984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
    Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL.
    Okegawa T; Kinjo M; Ohta M; Miura I; Horie S; Nutahara K; Higashihara E
    Int J Urol; 2003 Apr; 10(4):201-6. PubMed ID: 12657099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation.
    Kort SA; Martens F; Vanpoucke H; van Duijnhoven HL; Blankenstein MA
    Clin Chem; 2006 Aug; 52(8):1568-74. PubMed ID: 16762996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME
    Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Huber A; Lümmen G; Tscholl R
    Urology; 2000 Apr; 55(4):481-5. PubMed ID: 10736487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
    Jung K; Elgeti U; Lein M; Brux B; Sinha P; Rudolph B; Hauptmann S; Schnorr D; Loening SA
    Clin Chem; 2000 Jan; 46(1):55-62. PubMed ID: 10620572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of histological inflammation on total and free serum prostate-specific antigen values in patients without clinically detectable prostate cancer.
    Stimac G; Spajic B; Reljic A; Katusic J; Popovic A; Grubisic I; Tomas D
    Korean J Urol; 2014 Aug; 55(8):527-32. PubMed ID: 25132947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aggressiveness of inflammation in histological prostatitis--correlation with total and free prostate specific antigen levels in men with biochemical criteria for prostate biopsy.
    Stimac G; Reljic A; Spajic B; Dimanovski J; Ruzic B; Ulamec M; Sonicki Z; Kraus O
    Scott Med J; 2009 Aug; 54(3):8-12. PubMed ID: 19725275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.